Company intelligence / Profile preview
Immorta Bio
Miami Beach, Florida, United Statesimmortabio.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Preclinical
01
Overview
Immorta Bio has filed patents for treatments using its PMSC-11 stem cell therapy for liver failure, showing preservation of albumin production and prevention of liver enzyme rises. Their SenoVax™ platform has demonstrated successful inhibition of lung cancer growth in preclinical studies. The company is progressing toward clinical development with both platforms.
- Therapeutic areas
- OncologyOtherGastroenterologyCardiovascularInfectious Diseases
- Modalities
- Stem cell therapyCell therapyImmune cell therapyMesenchymal stem cell therapySenolytic immunotherapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Immorta Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immorta Bio.